Sponsor Pipeline

Beijing Pearl Biotechnology Limited Liability Company Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
4
Active Trials
2
Recruiting
3
Phase 3
3
Disease Areas
Active Trials by Phase
Phase 3
2
Phase 2/3
1
Phase 1/2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT05989542 A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) Non-small Cell Lung Cancer Recruiting
NCT06930794 A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive Non-Small Cell Lung Cancer Recruiting
Phase 2/3
NCT06105619 A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma… Glioblastoma Active, Not Recruiting
Phase 1/2
NCT07285148 A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer Not Yet Recruiting
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (3) Lung Cancer (3) Glioblastoma (1)
Get alerts when Beijing Pearl Biotechnology Limited Liability Company's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free